<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679989</url>
  </required_header>
  <id_info>
    <org_study_id>Met-IER2016</org_study_id>
    <nct_id>NCT02679989</nct_id>
  </id_info>
  <brief_title>The Impact Of An Intermittent Energy Restricted Diet On Insulin Sensitivity In Men and Women With Central Obesity</brief_title>
  <acronym>Met-IER</acronym>
  <official_title>A Randomised Controlled Trial Assessing The Impact Of An Intermittent Energy Restricted Diet On Weight Loss, Insulin Sensitivity and Heart Rate Variability In Men and Women With Central Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LighterLife (UK) Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An intermittent energy restricted (IER) diet may modify cardio-metabolic disease risk factors
      compared to an energy-matched continuous energy restricted (CER) diet. A randomised
      controlled parallel design trial will determine the impact of a short-term IER diet (2
      consecutive days of very low calorie diet (VLCD), 5 days moderate energy restriction each
      week for a 4 week period), compared to a CER diet, on insulin sensitivity in healthy
      (disease-free) subjects with central obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prediabetes rates in England have showed a marked increase, more than tripling between 2003
      and 2011. It is characterised by an impaired fasting glucose or impaired glucose tolerance
      that increases the risk of progression to type 2 diabetes (T2D). It has been estimated that
      approximately 90% of T2D is attributed to excess weight. Central obesity is a primary driver
      of increased cardiometabolic risk due to its lipotoxicity effects, promoting a
      proinflammatory state that facilitates insulin resistance and beta cell dysfunction. A high
      waist circumference measurement, indicative of central obesity, is associated with increased
      risk of cardiovascular diseases and T2D, and is a stronger predictor of T2D than BMI. BMI has
      limitations as an indicator of adiposity since it doesn't distinguish lean from fat mass, and
      does not indicate body fat distribution. Conventionally, continuous energy restriction (CER)
      diets have been used for weight loss, which consist of a constant daily energy deficit
      relative to total energy expenditure. The impact on weight loss and health of an intermittent
      energy restriction (IER) approach has only rarely been investigated (although the &quot;5:2 diet&quot;
      has been popularised in lifestyle books aimed at the general public). An IER diet consists of
      a predefined period of time severely restricting energy intake, alternated with a period of
      greater energy intake. This approach was shown to confer metabolic benefits in overweight and
      obese women at risk of breast cancer with baseline BMI of 2445 (Harvie et al., 2013Í¾ Harvie
      et al., 2011).

      Rationale: An IER diet using meal replacements (VLCD foodpacks used as total dietary
      replacements for 2 consecutive days each week, and a food-based energy-restricted diet for
      the other 5 days of the week) may modify cardio-metabolic disease risk factors compared to an
      energy-matched CER diet.

      Research question: In centrally obese subjects, assessed by a high waist circumference
      measurement, does adherence to an IER diet have enhanced cardio-metabolic benefits compared
      to a CER diet? Hypothesis: Increases in insulin sensitivity following a 4 week dietary
      intervention with an IER weight loss programme will be greater compared to a standard CER
      programme.

      Objectives:

        1. A randomised controlled parallel design trial will determine the impact of a short-term
           IER diet compared to a CER diet on primary outcome variables (insulin sensitivity) in
           healthy subjects with a high waist circumference.

        2. To assess the impact of an IER diet on secondary outcome variables, including body
           composition, heart rate variability (HRV, a measure of cardiac autonomic function,
           including parasympathetic and sympathetic activity), blood pressure, vascular function,
           other markers of insulin resistance, inflammation/adipokines, plasma lipid profile,
           plasma norepinephrine, ketosis, the gut microbiome and cognitive function in healthy
           subjects with a high waist circumference.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Revised QUICKI (RQUICKI)</measure>
    <time_frame>Baseline</time_frame>
    <description>Marker of insulin sensitivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RQUICKI</measure>
    <time_frame>day 29</time_frame>
    <description>Marker of insulin sensitivity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RQUICKI</measure>
    <time_frame>day 31</time_frame>
    <description>Marker of insulin sensitivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose concentration</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose concentration</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin concentration</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin concentration</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma non-esterified fatty acid concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma non-esterified fatty acid concentration</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma non-esterified fatty acid concentration</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma total cholesterol concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma total cholesterol concentration</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma total cholesterol concentration</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma low density lipoprotein (LDL) cholesterol concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma LDL cholesterol concentration</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma LDL cholesterol concentration</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma high density lipoprotein (HDL) cholesterol concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HDL cholesterol concentration</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HDL cholesterol concentration</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma triglyceride concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma triglyceride concentration</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma triglyceride concentration</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma total cholesterol:HDL cholesterol ratio</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma total cholesterol:HDL cholesterol ratio</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma total cholesterol:HDL cholesterol ratio</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis model assessment estimated insulin resistance (HOMA-IR)</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting (calculated from insulin and glucose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis model assessment estimated insulin resistance (HOMA-IR)</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting (calculated from insulin and glucose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis model assessment estimated insulin resistance (HOMA-IR)</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting (calculated from insulin and glucose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma adiponectin concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma adiponectin concentration</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma adiponectin concentration</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma leptin concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma leptin concentration</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma leptin concentration</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma interleukin-6 concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma interleukin-6 concentration</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma interleukin-6 concentration</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma beta-hydroxybutyrate concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma beta-hydroxybutyrate concentration</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma beta-hydroxybutyrate concentration</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma norepinephrine concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma norepinephrine concentration</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma norepinephrine concentration</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma soluble alpha-klotho concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma soluble alpha-klotho concentration</measure>
    <time_frame>day 29</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma soluble alpha-klotho concentration</measure>
    <time_frame>day 31</time_frame>
    <description>Fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index (BMI)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip circumference</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip circumference</measure>
    <time_frame>day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip circumference</measure>
    <time_frame>day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage body fat</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage body fat</measure>
    <time_frame>day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage body fat</measure>
    <time_frame>day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage lean body mass</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage lean body mass</measure>
    <time_frame>day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage lean body mass</measure>
    <time_frame>day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (resting)</measure>
    <time_frame>Baseline</time_frame>
    <description>supine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (resting)</measure>
    <time_frame>day 29</time_frame>
    <description>supine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (resting)</measure>
    <time_frame>day 31</time_frame>
    <description>supine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (ambulatory)</measure>
    <time_frame>24 h recording at baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (ambulatory)</measure>
    <time_frame>24 h recording on day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (ambulatory)</measure>
    <time_frame>24 h recording on day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (sleep-time)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (sleep-time)</measure>
    <time_frame>day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (sleep-time)</measure>
    <time_frame>day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (during mental stress)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (during mental stress)</measure>
    <time_frame>day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability (during mental stress)</measure>
    <time_frame>day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure 24 h</measure>
    <time_frame>24 h analysis at baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure daytime</measure>
    <time_frame>Daytime analysis at baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure night-time</measure>
    <time_frame>Night-time analysis at baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure 24 h</measure>
    <time_frame>24 h analysis on day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure daytime</measure>
    <time_frame>daytime analysis on day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure night-time</measure>
    <time_frame>night-time analysis on day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure 24 h</measure>
    <time_frame>24 h analysis on day 31</time_frame>
    <description>24 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure daytime</measure>
    <time_frame>Daytime analysis on day 31</time_frame>
    <description>day time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure night-time</measure>
    <time_frame>Night-time analysis on day 31</time_frame>
    <description>night-time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital volume pulse - stiffness index (SI)</measure>
    <time_frame>Baseline</time_frame>
    <description>Stiffness index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital volume pulse - SI</measure>
    <time_frame>day 29</time_frame>
    <description>Stiffness index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital volume pulse - SI</measure>
    <time_frame>day 31</time_frame>
    <description>Stiffness index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital volume pulse - reflection index (RI)</measure>
    <time_frame>Baseline</time_frame>
    <description>reflection index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital volume pulse - RI</measure>
    <time_frame>day 29</time_frame>
    <description>reflection index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital volume pulse - RI</measure>
    <time_frame>day 31</time_frame>
    <description>reflection index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mnemonic Similarity Test</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mnemonic Similarity Test</measure>
    <time_frame>day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mnemonic Similarity Test</measure>
    <time_frame>day 31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Power of food scale</measure>
    <time_frame>Baseline</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Power of food scale</measure>
    <time_frame>day 29</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Power of food scale</measure>
    <time_frame>day 31</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPE (not an acronym)</measure>
    <time_frame>Baseline</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPE</measure>
    <time_frame>day 29</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPE</measure>
    <time_frame>day 31</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline until endpoint: day 31 (+/-1 day)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Obesity, Abdominal</condition>
  <arm_group>
    <arm_group_label>Intermittent Energy Restriction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weight loss intervention: Intermittent Energy Restriction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous Energy Restriction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weight loss intervention: Continuous Energy Restriction</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intermittent Energy Restriction</intervention_name>
    <description>Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions</description>
    <arm_group_label>Intermittent Energy Restriction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Continuous Energy Restriction</intervention_name>
    <description>Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions</description>
    <arm_group_label>Continuous Energy Restriction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged &gt;35-75 years

          -  Waist circumference above cut-off for high risk of cardio-metabolic disease of &gt;102 cm
             in men with a Europid, Black African and Caribbean, and other ethnic background and
             &gt;88 cm in women with a Europid, Black African and Caribbean, and other ethnic
             background (WHO, 2008), and â¥90 cm in men and â¥80 cm in women with an Asian background
             (South Asian and East Asian) (Misra et al., 2009).

        REFERENCES Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. (2009).
        Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome
        for Asian Indians and recommendations for physical activity, medical and surgical
        management. The Journal of the Association of Physicians of India 57: 163170.

        WHO (2008). Waist circumference and waist-hip ratio: report of a WHO expert consultation.
        Geneva, 8-11 December 2008.

        Exclusion Criteria:

          -  Kidney or cardiovascular disease, cancer, diabetes, gastrointestinal or chronic liver
             diseaseÍ¾

          -  previous bariatric surgery or other major surgery (e.g. organ transplantation)Í¾

          -  unable to provide written informed consentÍ¾

          -  have significant psychiatric disorder (e.g. schizophrenia, anxiety, panic disorder,
             attention deficit disorder, post-traumatic stress disorder, obsessive compulsive
             disorder) or uncontrolled depressionÍ¾

          -  participated in a weight management drug trial in the previous 3 monthsÍ¾

          -  have binge eating behaviourÍ¾

          -  have uncontrolled epilepsyÍ¾

          -  alcohol or substance abuseÍ¾

          -  currently pregnant, lactating, or planning pregnancy within the study periodÍ¾

          -  are using medication clinically deemed to affect metabolic rate and weight (e.g. beta
             blockers, corticosteroids, diuretics, etc)Í¾

          -  lactose intolerant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy Hall, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes &amp; Nutritional Sciences Division, King's College London, Franklin-Wilkins Buiding, 150 Stamford St.</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Harvie M, Wright C, Pegington M, McMullan D, Mitchell E, Martin B, Cutler RG, Evans G, Whiteside S, Maudsley S, Camandola S, Wang R, Carlson OD, Egan JM, Mattson MP, Howell A. The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. Br J Nutr. 2013 Oct;110(8):1534-47. doi: 10.1017/S0007114513000792. Epub 2013 Apr 16.</citation>
    <PMID>23591120</PMID>
  </reference>
  <reference>
    <citation>Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G, Cuzick J, Jebb SA, Martin B, Cutler RG, Son TG, Maudsley S, Carlson OD, Egan JM, Flyvbjerg A, Howell A. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond). 2011 May;35(5):714-27. doi: 10.1038/ijo.2010.171. Epub 2010 Oct 5.</citation>
    <PMID>20921964</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2016</study_first_posted>
  <last_update_submitted>July 4, 2016</last_update_submitted>
  <last_update_submitted_qc>July 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Intermittent fasting</keyword>
  <keyword>Sympathetic nervous system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

